| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -19.5 | -9.8 |
| Net income | -20.3 | -10.2 |
| EPS (diluted, $ a share) | $-0.22 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CRVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Corvus Pharmaceuticals, Inc.: key numbers
- Share price
- $10.60Close, Nov 16
- Market cap
- $894M
- Shares outstanding
- 84.35MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Corvus Pharmaceuticals, Inc.
All →Corvus Pharmaceuticals Chief Business Officer Jeffrey Arcara Buys $34.4K of Stock
Jeffrey Arcara, Chief Business Officer, bought 3,000 shares of Corvus Pharmaceuticals, Inc. at $11.46 a share, worth $34.4K in total on Nov 11, 2026. Shares held after the trade: 3,000.
- Value
- $34.4K
- Shares
- 3,000
- Price
- $11.46
- Role
- Chief Business Officer
- Trade date
- Nov 11, 2026
Corvus Pharmaceuticals Financial Results
Corvus Pharmaceuticals reported third quarter 2026 financial results and provided a business update on its soquelitinib clinical programs. The company ended the quarter with $202.9 million in cash and marketable securities, which is expected to provide a financial runway into the second quarter of 2028.
“We continue to drive the science and advance the breadth of potential clinical indications for ITK inhibition with soquelitinib. Our Phase 3 PTCL and Phase 2 atopic dermatitis clinical trials are on track and there has been strong interest in our new hidradenitis suppurativa trial. We also are making good progress towards initiating a unique asthma trial that will include both T2 and non-T2 patients by Q1 2027. We believe soquelitinib has the potential to be effective in both types of asthma patients based on its mechanism of action affecting Th2, Th17 and T regulatory cells, which we will be closely analyzing in our hidradenitis suppurativa trial. Taken altogether, we are positioned for a series of potentially significant data milestones across our soquelitinib development pipeline in 2027.”
Richard A. Miller, M.D., co-founder, president and chief executive officer